About Symbiotec Pharmalab Limited
Data last updated: 21 December 2025
Symbiotec Pharmalab Limited is a public limited company based in Mhow, Madhya Pradesh, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 20 September 2002, the company has been in operation for over 24 years.
Registered with ROC Gwalior under CIN U24232MP2002PTC015293.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹12.34 Cr. Formerly known as Symbiotec Pharmalab Limited. It is led by directors including Rohit Brijmohan Mantri and Pratik Patel.
Last AGM: 26 September 2024. Financial statements filed for year ended 31 March 2024. Office: Mhow, Madhya Pradesh.
As per the financials filed for FY 2025, the company reported a revenue of ₹755.98 Cr, a growth of 5% compared to the previous year.
The company has a workforce of approximately 1,330 employees as per the latest available data. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand - Symbiotec. As per MCA filings, the company has open charges of ₹556.47 Cr and satisfied charges of ₹395.55 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website symbiotec.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address385/2 Pigdamber, Rau, Mhow, Madhya Pradesh, India – 453331
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited has one previous CIN (Corporate Identification Number): U24232MP2002PTC015293. The current CIN is U24232MP2002PLC015293, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232MP2002PLC015293 | Current |
| U24232MP2002PTC015293 | Previous |
Associated Brands with Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited operates one associated brand: Symbiotec. These brands represent Symbiotec Pharmalab Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Non-sterile steroid hormone-based APIs and intermediates are manufactured. | symbiotec.in |
Competitors & Alternatives of Symbiotec Pharmalab Limited
Brands and companies operating in the same space as Symbiotec Pharmalab Limited include Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Apicore
|
APIs are manufactured and custom synthesis services are provided. | Somerset, United States, United States | 2004 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Bellen Chemistry
|
APIs and intermediates are researched and manufactured, specializing in heterocycles. | Beijing, China, China | 2007 |
Business Activity of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is audited by S R B C & Co. Llp for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S R B C & Co. Llp | blur-value | blur-value | blur-value |
Board of Directors of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is currently managed by 6 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rohit Brijmohan Mantri
Also directs:
Symbiotec Biologics Private Limited, Symbiotec Zenfold Private Limited, Knovea Pharmaceutical Private Limited and 5 more
|
Nominee Director | 06 Dec 2018 | 7 Years 7 Months | Current |
|
Pratik Patel
Also directs:
Jash Engineering Ltd, Patamin Investments Private Limited, Jash Invent India Private Limited and 2 more
|
Director | 16 Dec 2025 | 0 Years 6 Months | Current |
|
Buggana Hariharnath
Also directs:
Symbiotec Zenfold Private Limited, Knovea Pharmaceutical Private Limited, Invascent Advisory Services India Llp and 5 more
|
Nominee Director | 16 Sep 2024 | 1 Years 9 Months | Current |
|
Sunita Kishnani
Also directs:
Jash Engineering Ltd
|
Director | 27 Nov 2025 | 0 Years 7 Months | Current |
| Anil Kumar Satwani | Officer In Default | 14 May 2005 | 21 Years 1 Months | Current |
| Richard Patrick Findlay Kenny | Director | 27 Nov 2025 | 0 Years 7 Months | Current |
Financials of Symbiotec Pharmalab Limited FY 2024 filings available
Symbiotec Pharmalab Limited reported revenue of ₹755.98 Cr (up 5% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Symbiotec Pharmalab Limited
As of FY 2024, Symbiotec Pharmalab Limited's shareholding pattern shows 25.08% by promoters, 74.92% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Symbiotec Pharmalab Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Symbiotec Zenfold Private Limited | U24100MP2020PTC052495 |
**.**%
|
| Knovea Pharmaceutical Private Limited | U24110MP2020PTC050978 |
**.**%
|
Showing major subsidiaries. Total: 2.
Charges & Borrowings of Symbiotec Pharmalab Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jul 2025 | State Bank of India | ₹25,000 | Open |
| 27 Sep 2024 | Sbicap Trustee Company Limited | ₹555.98 Cr | Open |
| 06 Feb 2019 | Yes Bank Limited | ₹49 Lakh | Open |
| 28 Jul 2022 | Axis Bank Limited | ₹1.99 Cr | Satisfied |
| 01 Mar 2018 | Hdfc Bank Limited | ₹1.25 Cr | Satisfied |
Total charge records: 18 View all charges
Employees and EPFO Compliance at Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited has a workforce of 1,330 employees as of Mar 27, 2025.
Employee Count & EPFO Data of Symbiotec Pharmalab Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Symbiotec Pharmalab Limited
GSTIN & GST Filing Data of Symbiotec Pharmalab Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Symbiotec Pharmalab Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Symbiotec Pharmalab Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Symbiotec Pharmalab Limited
MSME Payment Delays by Symbiotec Pharmalab Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Symbiotec Pharmalab Limited
Subsidiaries & Group Companies of Symbiotec Pharmalab Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Symbiotec Pharmalab Limited with ownership details.
MCA Filings & Documents of Symbiotec Pharmalab Limited
MCA Filings & Documents of Symbiotec Pharmalab Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Symbiotec Pharmalab Limited
Recent News on Symbiotec Pharmalab Limited
Frequently Asked Questions about Symbiotec Pharmalab Limited
Symbiotec Pharmalab Limited is an active public limited company in the pharma sector based in Mhow, Madhya Pradesh, India. It was incorporated on 20 September 2002 (24+ years old) and is registered under CIN U24232MP2002PLC015293. The company has 1,330 employees.
Symbiotec Pharmalab Limited reported revenue of ₹755.98 Cr for FY 2025 (up 5.00% YoY).
The current directors of Symbiotec Pharmalab Limited are:
The primary industry of Symbiotec Pharmalab Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Symbiotec Pharmalab Limited can be reached at the registered office: 3852 Pigdamber, Rau, Mhow, Madhya Pradesh, India – 453331, or through the website symbiotec.in.
The authorised capital is ₹30 Cr, and the paid-up capital is ₹12.34 Cr.